Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesClinical/Medical PolicyProvidence Health Plan Skin Substitutes Coverage U…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedProvidence Health PlanPolicy 16

    Skin and Tissue Substitutes

    Customize your policy alerts

    Sign up for Providence Health Plan Policy 16 alerts

    Get alerted when Policy 16 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing medical necessity and coverage criteria for skin and tissue substitute products used for burns, diabetic foot ulcers, venous stasis ulcers, traumatic wounds, select reconstructive procedures, and other specified indications for Providence Health Plan commercial products.

    Policy Summary
    PayerProvidence Health Plan
    PolicySkin and Tissue Substitutes
    Policy CodePolicy 16
    Change TypeApplication limits updatedcode set updates
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJan 1, 2027
    Key ActionObtain prior authorization for skin substitutes used for diabetic foot or venous stasis ulcers and document failure of ≥4 weeks of standard therapy and wound characteristics.
    SourceLink
    POLICY UPDATE CHANGES

    2/2026 Annual review updated application limits for venous stasis ulcers and diabetic foot (ulcers) and added examples to criterion I.

    Updated application limits for venous stasis ulcers and diabetic foot ulcers and added examples to criterion I.

    Multiple new CPT/HCPCS codes were added during periodic code set updates (Q1–Q4 2025 and Q1 2026).

    Annual review updated application limits for venous stasis ulcers and diabetic foot ulcers and added examples to criterion I.

    Multiple code set updates and new codes were added across Q2 2025, Q3 2025, Q4 2025, Q1 2026 and Q2 2026.

    Examples to criterion I. were added or expanded (entries reference examples 1–4).

    12max applications (DFU typical)
    1GraftJacket® limit (DFU)
    4 wksmin prior therapy duration
    ABI ≥0.70vascular adequacy threshold
    Commercial onlyplan applicability
    Many listedproducts NMN

    Coverage Criteria and Medical Necessity

    Breast reconstruction (ADM)

    FDA-approved allogenic Acellular Dermal Matrix (ADM) products may be considered medically necessary when used for medically necessary breast reconstruction surgery.

    Breast reconstruction (ADM): FDA-approved ADM products (eg, AlloDerm®, Cortiva®, Dermacell™, FlexHD®, FlexHD® Pliable™, GraftJacket®) used for medically necessary breast reconstruction surgery are considered medically necessary.

    See separate breast reconstruction policy for surgical indications.

    Burns — biosynthetic dressings and dermal regeneration products

    FDA-approved biosynthetic dressings and dermal regeneration/bilayer products may be medically necessary for certain burn indications when ALL criteria are met.

    Biosynthetic dressing for partial-thickness burns: Used as a temporary covering of a partial-thickness burn and applied to freshly debrided or excised wounds or meshed autografts containing <10^5 bacteria/g tissue.

    Includes products such as Biobrane/Biobrane-L; application should follow product IFU (hemostasis, fabric side down, immobilization).

    Policy Summary
    PayerProvidence Health Plan
    PolicySkin and Tissue Substitutes
    Policy CodePolicy 16
    Change TypeApplication limits updatedcode set updates
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJan 1, 2027
    Key ActionObtain prior authorization for skin substitutes used for diabetic foot or venous stasis ulcers and document failure of ≥4 weeks of standard therapy and wound characteristics.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityCoding, Billing Units, and Application CodesAuthorization, Documentation, and Billing Actions Providers Must TakeBackground, Definitions, and Evidence SummaryPolicy Revision History and Updates
    Dermal regeneration for deep burns: Used for post-excisional treatment of life-threatening full-thickness or deep partial-thickness thermal injuries when sufficient autograft is not available or not desirable due to patient physiology.

    Includes Integra® family of dermal regeneration and bilayer products; follow product labeling for indication and application.

    Cultured epidermal autografts (Epicel)

    Covered when used in accordance with FDA Humanitarian Device Exemption criteria.

    Cultured epidermal autograft (Epicel): Used for adult and pediatric patients with deep dermal or full-thickness burns comprising total body surface area ≥ 30% as specified in the FDA Humanitarian Device Exemption (HDE) labeling.TBS ≥ 30%

    Includes Epicel; product is HDE-approved and is subject to HDE-specific oversight and labeling.

    Diabetic foot ulcers

    Products listed may be medically necessary when ALL of the following are met:

    Diabetic foot ulcer coverage criteria: A. Skin substitute is used in conjunction with standard diabetic ulcer care (wound bed preparation, infection control, debridement, dressings, offloading where applicable); and B. Ulcer extends through the dermis but without tendon, muscle, joint, or bone exposure; and C. Ulcer size is ≥ 1 cm2 and ≤ 25 cm2; and D. Ulcer is free of infection; and E. Patient HbA1c (A1c) is < 12%; and F. Failure of at least 4 weeks of standard diabetic foot ulcer therapy (eg, surgical debridement, dressing changes); and G. Adequate blood supply to the foot defined by at least one of: (1) ABI ≥ 0.70 and/or (2) palpable pedal pulse; and H. Product application limited to no more than 12 applications over 12 weeks with a minimum of 1 week between applications (except GraftJacket® [Q4107] limited to one initial application).Ulcer size ≥1 cm² and ≤25 cm²; HbA1c <12%; ABI ≥0.70 or palpable pedal pulse; ≤12 applications (most products); GraftJacket® = 1

    Documentation must include wound characteristics, measurements, evidence of prior ineffective standard care and qualifying/disqualifying conditions.

    Venous stasis ulcers

    Products listed may be medically necessary when ALL of the following are met:

    Venous stasis ulcer coverage criteria: A. Skin substitute is used in conjunction with standard venous stasis ulcer care (eg, compression therapy and wound care measures); and B. Ulcer extends through the dermis but without tendon, muscle, joint, or bone exposure; and C. Ulcer size is ≥ 2 cm2 and ≤ 20 cm2; and D. Ulcer is free of infection; and E. Failure of at least 4 weeks of standard venous stasis therapy (eg, compression); and F. Adequate blood supply to the leg defined by at least one of: (1) ABI ≥ 0.70 and/or (2) palpable pedal pulse; and G. Any product-specific application limits apply as noted in the policy tables and coding sections.Ulcer size ≥2 cm² and ≤20 cm²; ABI ≥0.70 or palpable pedal pulse; failure ≥4 weeks

    Serial wound measurement and documentation recommended; reapplication may be considered while ulcer continues to respond (clinician discretion).

    Traumatic wounds

    FDA-approved skin and tissue substitutes may be considered medically necessary for traumatic wounds when autografting is not possible.

    Traumatic wound product categories: Covered product categories include biosynthetic dressings (eg, Biobrane®/Biobrane®-L), cultured epidermal autografts (eg, Epicel), Integra dermal regeneration and bilayer products, and human fibroblast-derived temporary skin substitutes (eg, TransCyte®).

    Indicated when autografting is not possible; follow product labeling and ensure proper wound bed preparation and hemostasis prior to application.

    Other covered indications

    Genital surgery component: Use of a skin substitute as a component of genital surgery may be medically necessary for surgical wound coverage prior to skin grafting when the member meets medical necessity criteria for gender-affirming surgery.

    Document member meets medical necessity criteria for the primary genital surgery.

    Prevention of Frey's syndrome: Use of a skin substitute may be medically necessary to prevent Frey's Syndrome after parotidectomy.

    Use supported by evidence indicating reduced incidence versus no graft in pooled trials.

    Repeat treatment

    Repeat treatment of diabetic foot ulcers or venous stasis ulcers after the initial 12-week period may be medically necessary when ALL of the following wound documentation criteria are met:

    Repeat treatment documentation: A. Number and position of ulcers; and B. Wound measurements for each ulcer including length, width, and depth; and C. Descriptions of wound edge parameters, wound base quality, drainage, and infection.

    Repeat treatments are considered only when documentation shows the ulcer continues to improve on serial assessment.

    Not Medically Necessary

    Products and coverage stance:

    Not Medically Necessary list: A long list of specific named skin and tissue substitute products are designated Not Medically Necessary in the policy.

    See product listings in policy (chunks 18–20 and coding tables) for the full list of named NMN products.

    Clinical prerequisites / Documentation

    General clinical prerequisites for use of skin substitutes:

    Prerequisites: Application of skin substitutes requires absence of infection, proper wound bed preparation, hemostasis, and documentation of prior ineffective standard care including duration.

    Medical record must include wound characteristics, measurements, prior ineffective standard care (duration), and qualifying/disqualifying conditions (eg, HbA1c, ABI).

    Products and labeled indications (informational for coverage decisions)

    Products are described with FDA-labeled indications which are referenced in policy criteria elsewhere.

    Product-specific labeled indications: Examples include AlloDerm for repair/replacement of integumental tissue; Apligraf for certain venous and diabetic foot ulcers unresponsive to conventional therapy; Dermagraft for full-thickness DFUs; Integra products for burns and DFUs; TheraSkin for chronic wounds including DFUs and VLUs.

    Refer to FDA labeling and product IFU for specific application instructions and approved indications when documenting medical necessity.

    Evidence-based coverage considerations for DFUs and VLUs

    Systematic reviews (Hayes, Cochrane) summarize low to very low quality evidence that skin substitutes as adjuncts to standard wound care increase healing rates in chronic DFUs and VLUs; comparative superiority between product types is inconclusive.

    Effect on ulcer healing: Multiple RCTs and observational studies report higher incidence of complete healing when skin substitutes are added to standard wound care compared to standard care alone across diabetic foot ulcers and venous leg ulcers, but overall evidence quality is low to very low.

    See Hayes and Cochrane systematic reviews for pooled effect estimates and quality assessments.

    Effect on amputation: Available evidence does not consistently demonstrate reduced amputation incidence in RCTs; retrospective studies report mixed findings.

    Hayes reviews identified limited and inconsistent data on amputation outcomes.

    Comparative effectiveness: Trials comparing cellular versus acellular substitutes show mixed results with no definitive conclusion that one category is superior.

    Results vary across studies; product choice should be justified in documentation.

    Medically necessary indications (by evidence)

    Medical necessity supported when product-specific peer-reviewed evidence demonstrates improved clinical outcomes as described below (product-specific evidence summarized in policy):

    Diabetic foot ulcer (DFU): Skin substitutes with RCT or systematic review evidence (eg, Apligraf, Dermagraft, Grafix, Integra, EpiFix) as adjuncts to standard care have demonstrated increased rates of complete ulcer healing and may be considered medically necessary when used with standard wound care.per cited trials

    Supported by Cochrane and Hayes reviews and individual RCTs (eg, Integra RCT showing 51% vs 32% closure).

    Venous leg ulcer (VLU): Certain products (eg, EpiFix, Apligraf) have RCT evidence showing improved complete healing when used with compression/standard care and may be considered medically necessary when used adjunctively.per cited trials

    Examples include RCTs reporting 60% vs 35% healing at 12 weeks for EpiFix + compression versus standard care.

    Burn wounds: Biosynthetic dressings (eg, Biobrane), dermal regeneration products (Integra), cultured epidermal autografts (Epicel), and human fibroblast-derived temporary substitutes (TransCyte) have peer-reviewed evidence supporting use as temporary or definitive treatments for burn wounds.per product labeling and trial data

    Refer to product-specific evidence tables in the policy.

    Breast reconstruction: Allogenic acellular dermal matrices (eg, AlloDerm, FlexHD) are established and supported in the literature for breast reconstruction.per product evidence

    See cited studies in the evidence tables.

    Prevention of Frey's syndrome: Acellular dermal matrix grafts (including AlloDerm) reduce incidence of Frey's syndrome versus no graft in pooled RCTs and may be considered clinically effective for prevention after parotidectomy.per meta-analyses

    Evidence summarized in policy evidence tables.

    Tympanic membrane repair: AlloDerm has retrospective study support showing similar closure rates to temporalis fascia with potential shorter healing or operative time; evidence quality is low and conclusions are limited.per retrospective studies

    Use considered investigational/insufficient for routine coverage for tympanic membrane perforation repair.

    Not medically necessary / Insufficient evidence

    Not medically necessary when ANY of the following conditions are present:

    Insufficient evidence: Product lacks peer-reviewed literature demonstrating safety and clinical utility.evidence absent

    Products without published evidence are designated not medically necessary.

    Poor-quality evidence: Available literature is inadequate due to poor study quality, high risk of bias, small heterogeneous populations, lack of randomized controlled design, lack of control groups, or short follow-up.poor quality studies

    Such products are designated not medically necessary until higher-quality evidence is available.

    Lack of FDA clearance: Product requires but has not received FDA 510(k) or PMA clearance/approval for the intended use.no FDA clearance

    Absence of necessary FDA regulatory clearance supports designation as not medically necessary.

    Hernia repair with biologic mesh: Use of biologic mesh for ventral or inguinal hernia repair lacks high-quality evidence of benefit over synthetic mesh and may be associated with higher recurrence or complications; this indication is considered not medically necessary or restricted depending on product and context.per Hayes reviews

    Hayes reviews found no clear advantage for biologic over synthetic mesh.

    Covered Indications (select products and uses)

    Evidence supports use of select skin substitute products for some indications; guidance and recommendations summarized below.

    Supported indications: Select skin substitutes are supported for breast reconstruction, burn wounds, diabetic foot ulcers, and venous stasis ulcers based on available evidence and guideline recommendations.

    NICE recommends dermal/skin substitutes as adjuncts for DFUs when healing has not progressed; SVS/AVF supports cultured bilayer replacements for difficult-to-heal VLUs after 4–6 weeks of standard care.

    Insufficient evidence / Not established indications

    The evidence is insufficient to establish safety and medical necessity for these indications due to low-quality or limited studies.

    Not established uses: Use of skin substitutes for hernia repair (allograft biologic mesh), tympanic membrane perforation repair, complex nasal reconstruction, rotator cuff tear repair, repair of non‑traumatic surgical wounds (eg, Mohs surgery), and other off‑label surgical indications is not established due to limited/low-quality evidence.

    Higher-quality RCTs and comparative studies are required to establish safety and effectiveness for these indications.

    Add-on product coverage criteria

    Covered when billed correctly as add-on to a primary procedure with corresponding Q-code:

    Add-on coding requirement: Skin and tissue substitute products must be billed as 'list separately' add-on items in addition to the primary procedure using the specified Q-code for the product and reported in the correct billing unit (per cm2, per 0.5 cc, per cc, or per mg as applicable).

    Refer to the policy coding tables for the exact Q-code mapping and unit of measure; failure to bill as add-on with the required Q-code may result in denial.

    Revisions to coverage application limits

    Policy revisions affecting coverage criteria

    Annual review 2/2026: Updated application limits for venous stasis ulcers and diabetic foot ulcers; examples were added to criterion I during the 2/2026 annual review.application limits updated

    See policy revision history and main criteria for the updated application limits and examples.

    Policy Revision History

    This section lists historical edits to the policy rather than coverage decision criteria.

    Revision history: Multiple annual and quarterly updates to CPT/HCPCS code sets and policy criteria were recorded; application limits for venous stasis ulcers and diabetic foot ulcers were updated and examples added to criterion I during annual reviews.

    Revision history documents code additions and periodic code set updates (Q2‑Q4 2024 through Q2 2026).

    The policy excludes several surgical and reconstructive applications where evidence is insufficient to support skin or tissue substitute use. Specifically, use for complex nasal reconstruction, tympanic membrane perforation, hernia repair, rotator cuff tear repair, and repair of non‑traumatic surgical excisions (e.g., Mohs surgery) is considered not medically necessary when the policy’s medically necessary indications or product criteria are not met.

    The policy contains an extensive list of brand‑named products designated Not Medically Necessary. Any product not listed as covered in the policy tables is considered not medically necessary; see the policy product list for many specific examples (e.g., Endoform, AmnioFix variants, Graftjacket® Xpress listings, Axolotl grafts, Strattice, and numerous amniotic/placental membrane and synthetic matrices).

    FDA approval or clearance alone is not sufficient to establish medical necessity or guarantee coverage. Regulatory status is informational; coverage decisions require that the product and its intended use meet the plan’s medical necessity criteria and documentation requirements.

    Products that lack peer‑reviewed evidence of safety or clinical utility, have only poor‑quality or heterogeneous studies, or require but have not obtained FDA 510(k)/PMA clearance are designated Not Medically Necessary. The policy further states that any skin or tissue substitute not listed as covered in the policy tables is considered not medically necessary.

    The evidence is insufficient to establish safety and medical necessity for repair of non‑traumatic surgical wounds (for example, Mohs surgery for squamous or basal cell carcinomas). Existing studies are small, nonrandomized, and of low methodological quality; higher‑quality data are required to support coverage for these indications.

    Text reserved for future content or administrative use.

    Many products in the policy are defined as add‑on, list separately items and must be billed using the specified Q‑code or other listed code and the correct billing unit (e.g., per cm2, per cc, or per mg). Billing an add‑on product outside of its designated list‑separately use or without the specified code is not supported by the policy and may result in claim denial or pricing adjustments.

    If an unlisted code is submitted for a non‑covered service addressed by this policy, it will be denied as not covered. For potentially covered services using unlisted codes, prior authorization is recommended to avoid post‑service denial.

    Historic revisions note that investigational criteria were changed to Not Medically Necessary in prior updates (e.g., 3/2023). These revision entries reflect edits to the policy’s investigational and NMN designations rather than new clinical criteria.

    The 2/2026 annual review updated application limits for venous stasis ulcers and diabetic foot ulcers and added examples to criterion I. These operational changes to application limits and illustrative examples may affect coverage determinations and billing when assessing prior authorization or claim adjudication.

    Revision‑history entries document multiple quarterly and annual code‑set updates and record that examples were added to criterion I. These history notes summarize administrative updates and do not by themselves contain new exclusion criteria; consult the main policy sections for explicit coverage determinations.

    Revision history records a series of code set updates across 2024–2026 and reiterates that application limits for venous stasis and diabetic foot ulcers were updated during the 2/2026 annual review. These entries are administrative and should prompt use of the current code sets when billing or requesting authorization.

    The policy states that unlisted products and codes are treated as not medically necessary unless explicitly listed as covered. Any skin or tissue substitute not appearing in the covered tables should be presumed Not Medically Necessary and subject to denial unless documentation supports an exception and prior authorization has been obtained.

    Numerous named products are specifically listed as Not Medically Necessary in the policy product tables. Providers should reference the policy’s NMN lists for product‑level coverage status before submitting claims; billing one of these listed products for a non‑covered indication may lead to denial.

    The policy reiterates that FDA clearance or approval does not by itself establish medical necessity. Regulatory status is provided for context but coverage requires that the use meets the plan’s clinical criteria and documentation standards.

    Products without adequate peer‑reviewed support, with poor‑quality literature, or lacking required FDA clearance are designated Not Medically Necessary. Examples include products where evidence is absent or studies are methodologically weak.

    Several off‑label surgical applications (hernia repair with biologic mesh, tympanic membrane repair with AlloDerm, complex nasal reconstruction, rotator cuff repair, and repair of non‑traumatic surgical wounds) are supported only by limited nonrandomized or retrospective evidence. Because of methodological limitations, these indications are considered not established and generally not medically necessary pending high‑quality evidence.

    Text reserved for future content or administrative use.

    All unlisted codes are reviewed at the claim level for medical necessity, correct coding, and pricing. Consistent with the policy, an unlisted code submitted for a non‑covered service will be denied as not covered.

    Historical revision notes indicate items previously categorized as investigational were reclassified to Not Medically Necessary in earlier updates (for example, entries in 3/2023). These entries summarize prior editorial decisions rather than add new clinical exclusions.

    Revision history documents that application limits for venous stasis ulcers and diabetic foot ulcers were updated during the 2/2026 annual review; providers should verify that claims and prior authorization requests comply with the updated application limits as these may affect coverage.

    Many revision‑history entries refer to added examples to criterion I and multiple code set updates through Q2 2026. These administrative updates do not replace the main policy criteria; consult the coverage sections for the specific clinical and numeric limits that determine medical necessity.

    The revision history section is an administrative log of code and criteria changes and does not itself specify Not Medically Necessary conditions; for NMN statements consult the policy’s main coverage and exclusion sections.

    Coding, Billing Units, and Application Codes

    Referenced HCPCS example and product-specific limitHCPCSCovered
    Q4107GraftJacket® Regenerative Tissue Matrix (as listed and limited in policy)
    Products listed as Not Medically Necessary (by name)mixedNot Covered
    No codes listed
    Regulatory pathways mentioned (informational)mixed
    No codes listed
    Recommended diagnosis codes for vocal cord paralysis treatmentICD-10
    J38.02Paralysis of vocal cords and larynx, bilateral
    J38.00Paralysis of vocal cords and larynx, unspecified
    J38.01Paralysis of vocal cords and larynx, unilateral
    Procedure CPT/HCPCS codes (applications and harvest/preparation codes)mixedCovered
    15011Harvest of skin for skin cell suspension autograft; first 25 sq cm or less.
    15012Harvest of skin for skin cell suspension autograft; each additional 25 sq cm or part thereof.
    15013Preparation of skin cell suspension autograft, requiring enzymatic processing; first 25 sq cm or less of harvested skin.
    15014Preparation of skin cell suspension autograft; each additional 25 sq cm of harvested skin.
    15015Application of skin cell suspension autograft to wound and donor sites; first 480 sq cm or less.
    15016Application of skin cell suspension autograft; each additional 480 sq cm or part thereof.
    15017Application of skin cell suspension autograft to specified areas; first 480 sq cm or less.
    15018Application of skin cell suspension autograft to specified areas; each additional 480 sq cm or part thereof.
    15272Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less.
    15777Implantation of biologic implant (eg, acellular dermal matrix) for soft tissue reinforcement (ie, breast, trunk).
    1–10 of 15
    1/2
    HCPCS add-on product codesHCPCS
    A2001Innovamatrix ac, per square centimeter (add-on)
    A2002Mirragen advanced wound matrix, per square centimeter (add-on)
    A2004Xcellistem, 1mg Microlyte matrix, per square centimeter (add-on)
    A2005Microlyte matrix, per square centimeter (add-on)
    A2006Novosorb synpath dermal matrix, per square centimeter (add-on)
    A2007Restrata, per square centimeter (add-on)
    A2008Theragenesis, per square centimeter (add-on)
    A2009Symphony, per square centimeter (add-on)
    A2010Apis, per square centimeter (add-on)
    A2012Suprathel, per square centimeter (add-on)
    1–10 of 32
    1/4
    Products listed as Not Medically Necessary (by name)mixedNot Covered
    No codes listed
    Regulatory pathways mentioned (informational)mixed
    No codes listed
    Recommended diagnosis codes for vocal cord paralysis treatmentICD-10
    J38.02Paralysis of vocal cords and larynx, bilateral
    J38.00Paralysis of vocal cords and larynx, unspecified
    J38.01Paralysis of vocal cords and larynx, unilateral
    Procedure CPT/HCPCS codes (applications and harvest/preparation codes)mixedCovered
    15011Harvest of skin for skin cell suspension autograft; first 25 sq cm or less.
    15012Harvest of skin for skin cell suspension autograft; each additional 25 sq cm or part thereof.
    15013Preparation of skin cell suspension autograft, requiring enzymatic processing; first 25 sq cm or less of harvested skin.
    15014Preparation of skin cell suspension autograft; each additional 25 sq cm of harvested skin.
    15015Application of skin cell suspension autograft to wound and donor sites; first 480 sq cm or less.
    15016Application of skin cell suspension autograft; each additional 480 sq cm or part thereof.
    15017Application of skin cell suspension autograft to specified areas; first 480 sq cm or less.
    15018Application of skin cell suspension autograft to specified areas; each additional 480 sq cm or part thereof.
    15272Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less.
    15777Implantation of biologic implant (eg, acellular dermal matrix) for soft tissue reinforcement (ie, breast, trunk).
    1–10 of 15
    1/2
    HCPCS add-on product codesHCPCS
    A2001Innovamatrix ac, per square centimeter (add-on)
    A2002Mirragen advanced wound matrix, per square centimeter (add-on)
    A2004Xcellistem, 1mg Microlyte matrix, per square centimeter (add-on)
    A2005Microlyte matrix, per square centimeter (add-on)
    A2006Novosorb synpath dermal matrix, per square centimeter (add-on)
    A2007Restrata, per square centimeter (add-on)
    A2008Theragenesis, per square centimeter (add-on)
    A2009Symphony, per square centimeter (add-on)
    A2010Apis, per square centimeter (add-on)
    A2012Suprathel, per square centimeter (add-on)
    1–10 of 32
    1/4
    Covered HCPCS/C Codes and application codesHCPCSCovered
    C1763Connective tissue, non-human (includes synthetic)
    C1781Connective tissue, non-human (includes synthetic)
    C1832Mesh (implantable)
    C5271Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
    C5272Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof
    C5273Application of low cost skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area
    C5276Application of low cost skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
    C5277Application of low cost skin substitute graft to face/... up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof
    C5278Application of low cost skin substitute graft to face/... greater than or equal to 100 sq cm; first 100 sq cm wound surface area
    C9354Veritas collagen matrix, cm2
    1–10 of 16
    1/2
    Application codes for premarket/510(k)/361 HCT/P non-sheet productsHCPCSCovered
    G0681Application of a premarket approval (PMA), 510(k), 361 HCT/P non-sheet form skin substitute for a wound surface area up to 100 sq cm; first 25 sq cm or less
    G0682Application of a PMA/510(k)/361 HCT/P non-sheet form skin substitute for a wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area
    G0683Application of a PMA/510(k)/361 HCT/P non-sheet form skin substitute graft for a wound surface >= 100 sq cm; first 100 sq cm
    G0684Application of a PMA/510(k)/361 HCT/P non-sheet form skin substitute graft for a wound surface >= 100 sq cm; each additional 100 sq cm
    Q-codes and product-specific HCPCS Q-codes (add-on / per area or per unit)HCPCSCovered
    Q4100Skin substitute, not otherwise specified (add-on, list separately in addition to primary procedure)
    Q4101Apligraf, per square centimeter
    Q4102Oasis wound matrix / Oasis burn matrix / Integra bilayer matrix wound dressing, per square centimeter
    Q4103Integra bilayer matrix wound dressing / Integra dermal regeneration template, per square centimeter
    Q4104Integra dermal regeneration template (DRT) or omnigraft dermal regeneration matrix, per square centimeter
    Q4105Integra dermal regeneration template / omnigraft (add-on)
    Q4106Dermagraft, per square centimeter
    Q4107Graftjacket, per square centimeter
    Q4108Integra matrix, per square centimeter
    Q4111Primatrix / Gammagraft, per square centimeter
    1–10 of 53
    1/6
    A-codes (add-on per product/unit) referencedHCPCS
    A2023Add-on product code referenced in billing guidelines
    A2024Add-on product code referenced in billing guidelines
    A2025Add-on product code referenced in billing guidelines
    A2026Add-on product code referenced in billing guidelines
    A2027Add-on product code referenced in billing guidelines
    A2028Add-on product code referenced in billing guidelines
    A2029Add-on product code referenced in billing guidelines
    A2030Add-on product code referenced in billing guidelines
    A2031Add-on product code referenced in billing guidelines
    A2032Add-on product code referenced in billing guidelines
    1–10 of 23
    1/3
    Add-on Q Codes mapped to productsHCPCSCovered
    Q4152Dermavest and plurivest, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4153Biovance, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4154Neoxflo or clarixflo, 1 mg (add-on, list separately in addition to primary procedure)
    Q4155Neox 100 or clarix 100, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4156Revitalon, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4157Kerecis omega3, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4158Affinity, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4159Nushield, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4160Bio-connekt wound matrix, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4161Woundex flow, bioskin flow, 0.5 cc (add-on, list separately in addition to primary procedure)
    1–10 of 20
    1/2
    HCPCS Q-codes and product descriptorsHCPCS
    Q4290Membrane wrap-hydro, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4291Lamellas xt, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4292Lamellas, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4293Acesso dl, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4294Amnio quad-core, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4295Amnio tri-core amniotic, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4296Rebound matrix, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4297Emerge matrix, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4298Amniocore pro / Amnicore pro+, per square centimeter (add-on, list separately in addition to primary procedure)
    Q4299Amniocore pro+, per square centimeter (add-on, list separately in addition to primary procedure)
    1–10 of 135
    1/14
    Code set updates referencedmixed
    affected codesMultiple unspecified CPT/HCPCS codes were added/updated across Q2‑Q4 2024 and Q1‑Q2 2025 code set updates as noted in the revision history.
    Code set updates (general)mixed
    codes addedMultiple unspecified CPT/HCPCS codes were added in various code set updates (10/2024–Q1 2026).
    Code set updates (general)mixed
    codes addedMultiple unspecified CPT/HCPCS codes were added in various code set updates (Q3–Q4 2024 through Q1 2026) as noted in policy revision history.
    Code set updates (quarterly)mixed
    No codes listed
    Code set updates (no explicit codes listed)mixed
    No codes listed
    Ulcer size — diabetic and venous ulcer size thresholds
    Diabetic foot ulcer sizeUlcer size must be ≥1 cm² and ≤25 cm² for diabetic foot ulcers.
    Venous stasis ulcer sizeUlcer size must be ≥2 cm² and ≤20 cm² for venous stasis ulcers.
    Application limits (frequency)Diabetic foot skin substitutes are limited to no more than 12 applications over 12 weeks with at least 1 week between applications (GraftJacket® [Q4107] limited to 1 initial application).
    Infection statusUlcer must be free of infection at time of application.
    Tissue depth requirementUlcer must extend through the dermis but without exposure of tendon, muscle, joint, or bone.
    A1c — HbA1c threshold for coverage
    HbA1c thresholdPatient HbA1c (A1c) must be less than 12% for diabetic foot ulcer coverage.
    Documentation of levelMedical record must document the measured HbA1c value.
    Role in eligibilityA1c is a qualifying condition required alongside wound characteristics and prior therapy failure.
    Vascular adequacy — ABI or palpable pulse threshold
    ABI thresholdAdequate blood supply defined as ankle-brachial index (ABI) ≥ 0.70.
    Alternative vascular signOr the presence of a palpable pedal pulse satisfies vascular adequacy.
    Requirement contextVascular adequacy is required for diabetic foot and venous stasis ulcer coverage in addition to other criteria.
    Documentation thresholds — required medical record elements for coding support
    Required wound documentationMedical records must document wound/ulcer characteristics and wound measurements (length, width, depth).
    Prior care evidenceMust document evidence of prior ineffective standard care, including duration of treatment (e.g., ≥4 weeks).
    Qualifying/disqualifying conditionsRecords must include qualifying/disqualifying conditions such as HbA1c and ABI to support coding and medical necessity.
    Humanitarian device patient limit — HDE threshold referenced
    HDE patient limitHumanitarian Device Exemption applies to conditions affecting fewer than 4,000 individuals in the U.S. per year.
    IRB oversightHDE-labeled devices require use in IRB‑approved facilities with IRB oversight of usage.
    Effectiveness statementHDE labeling indicates effectiveness has not been demonstrated; marketing is allowed on limited basis under HDE conditions.
    Wound surface area billing thresholds — CPT first units and add-on units described
    First-unit area CPT thresholdsMultiple CPT area-based codes specify first-unit thresholds (examples: first 25 sq cm, first 100 sq cm, first 480 sq cm) to determine the initial billed unit.
    Additional-area add-on unitsSeparate add-on codes report each additional area increment (e.g., each additional 25 sq cm, each additional 100 sq cm, each additional 480 sq cm).
    Face/complex site reportingSpecific codes exist for face/scalp/orifices with their own first/additional area rules (first 25 sq cm; additional 25 sq cm increments or first 100 sq cm as noted).
    Wound surface area reporting — first/additional square centimeter reporting rules
    Area reporting rules (examples)Report first 25 sq cm and each additional 25 sq cm for many skin substitute application codes (also first 100 sq cm and each additional 100 sq cm for larger-area codes).
    Large-area codesFor codes with 480 sq cm blocks (skin cell suspension grafts), report first 480 sq cm then each additional 480 sq cm as applicable.
    Face/hand/foot reportingSeparate area-based reporting applies for face/scalp/eyelids/mouth/neck/genitalia/hands/feet/multiple digits with specified first/additional area thresholds.
    Billing units — per cm2, per 0.5 cc, per cc, per mg per-product unit descriptors
    Common billing unit typesProducts are billed per square centimeter (cm²), per 0.5 cc, per cc, or per mg depending on product—use the exact per-product unit specified in Q-/C-/A-codes.
    Add-on (list separately) requirementMany Q‑codes are designated as add-on and must be reported in addition to the primary procedure; billing units correspond to the unit descriptor (per cm², per cc, per mg).
    Code-level specificityUse the product-to-Q-code mapping in the policy to determine the exact billing unit and unit increment for each specific product.
    application limits for venous stasis ulcers and diabetic foot — updated application limits referenced (numeric details in source)
    Updated application limits noted2/2026 annual review updated application limits for venous stasis ulcers and diabetic foot ulcers; providers should reference the revised limits in the policy.
    Frequency/detail locationExact numeric or frequency changes to application limits are recorded in the policy revision entries; consult the main criteria sections for current numeric limits (e.g., ≤12 applications for most DFU products; exceptions noted).
    Examples added to criterion IExamples to criterion I were added during the 2/2026 review to guide application of limits and clinical decision-making.
    None specified — placeholder
    No additional items specifiedNo additional threshold details specified in this subsection beyond those documented elsewhere in the policy revision history.
    Revision-history noteRevision history documents code set updates and application-limit edits; consult the main policy text for operational thresholds.

    Authorization, Documentation, and Billing Actions Providers Must Take

    Prior Authorization

    Obtain prior authorization for ulcer-directed skin substitutes

    Prior authorization is required for skin substitutes used to treat diabetic foot ulcers or venous stasis ulcers when the policy criteria are applied (including limits on ulcer size, vascular adequacy, A1c, failure of standard therapy, and application limits such as ≤12 applications over 12 weeks except where product-specific limits apply).

    • Diabetic foot ulcer PA: criteria A–H including ulcer size (1–25 cm²), HbA1c <12%, failure of ≥4 weeks standard therapy, ABI ≥0.70 or palpable pedal pulse, and ≤12 applications over 12 weeks (GraftJacket® limited to 1).
    • Venous stasis ulcer PA: criteria A–F including ulcer size (2–20 cm²), failure of ≥4 weeks standard venous therapy (eg, compression), and vascular adequacy requirements.
    Denial Risk

    Expect denial for products listed as Not Medically Necessary

    Many named products are listed in the policy as Not Medically Necessary; providers should expect coverage denial if billing those products without meeting an applicable covered indication or prior authorization.

    • See the extensive Not Medically Necessary product lists (policy chunks 18–27) when selecting products for billing.
    • Billing a listed NMN product for an unsupported indication may result in denial.
    Prior Authorization

    FDA clearance does not substitute for medical necessity documentation

    FDA clearance or approval is informational only; coverage requires that the medical necessity criteria in the policy be met and documented (for example, appropriate wound preparation such as debridement and infection control).

    • Do not rely on FDA clearance alone to justify coverage — document how the patient meets policy medical necessity criteria and product IFU-based application requirements.
    Prior Authorization

    Coverage requires product‑specific peer‑reviewed evidence

    Coverage determinations depend on product‑specific peer‑reviewed evidence; products lacking published support, of poor study quality, or without required FDA clearance are considered not medically necessary.

    • When requesting coverage, reference peer‑reviewed studies that support clinical benefit for the specific product and indication.
    Prior Authorization

    PA may be required and claims risk denial without wound documentation

    Prior authorization may be required for many skin substitute products and associated procedure codes; claims submitted without supporting wound care documentation (eg, debridement, dressing changes) may be denied or audited.

    • Affected procedure and add-on codes are listed in the billing tables; ensure wound care documentation accompanies PA/claim submission.
    Prior Authorization

    Review PA requirements for G0681–G0684 non‑sheet HCT/P application codes

    Application codes for PMA/510(k)/361 HCT/P non‑sheet form skin substitutes (G0681–G0684) report area‑based first/each‑additional units and should be reviewed for prior authorization per plan procedures.

    • Use G0681–G0684 for non‑sheet HCT/P products and confirm PA requirements before billing.
    Billing Rule

    Report add‑on products using the specified Q‑codes

    Add‑on skin/tissue substitute products must be reported using the specified HCPCS Q‑code(s) for that product and unit of measure when billing as 'list separately' add‑on items.

    • Select the exact Q‑code mapped to the product in the policy tables and include corresponding documentation supporting per‑cm2, per‑cc, or per‑mg billing.
    Prior Authorization

    Obtain PA for unlisted codes to avoid post‑service denial

    Prior authorization is recommended for unlisted codes and potentially covered services to avoid post‑service denial; unlisted codes are reviewed at claim level and PA can prevent post‑service denials.

    • If using an unlisted code for a potentially covered service, obtain PA to reduce risk of denial.
    Note

    Use current code sets — PA linkage to code updates

    Prior authorization requirements and review expectations are tied to current code sets; providers should use current (post‑update) codes because PA processes may change when codes are added or revised.

    • Track quarterly and annual code set updates referenced in the policy revision history and confirm PA applicability to new codes.
    Note

    Revision history does not define PA procedures

    The provided revision‑history excerpts do not specify procedural prior authorization instructions; refer to the main prior authorization section and payer provider resources for PA procedures.

    • Revision history documents code changes but does not replace PA process guidance.
    Note

    Update PA processes for recent code set changes

    Multiple code set updates were made between 10/2024 and Q1 2026; prior authorization workflows may need to be updated to reference the new/termed codes added during these updates.

    • Confirm PA checklists and code lists reflect Q1 2026 and subsequent updates.
    Note

    Confirm PA impact after code set updates

    Code set updates are recorded frequently (quarterly); providers should confirm which specific codes require PA because the revision history indicates codes were added and termed across multiple updates.

    • Verify PA requirements for newly added Q‑codes and CPT/HCPCS codes prior to claim submission.
    Note

    Revision history lacks PA submission details

    Revision‑history excerpts in the document do not include prior authorization procedural detail; consult the policy's authorization/prior_auth section or payer portal for how to submit PAs.

    • Revision notes summarize code and criteria changes but not PA submission steps.
    Note
    Note
    Step Therapy

    Document failure of ≥4 weeks of standard therapy before coverage

    For diabetic foot ulcers and venous stasis ulcers, coverage of skin substitutes requires documented failure of at least 4 weeks of standard therapy (eg, debridement and dressing changes for DFU; compression therapy for VLU) before application.

    • Document duration and details of prior standard care (minimum 4 weeks) in the medical record before requesting coverage.
    Documentation Required

    Document prior standard wound care measures before skin substitute use

    Standard wound care prerequisites must be documented — wound bed preparation, infection control, dressings, offloading/compression as applicable — and show prior ineffective standard care before considering skin substitutes.

    • Include specifics of wound bed preparation and measures used during the prior therapy period.
    Documentation Required

    Justify product choice when cellular vs acellular alternatives exist

    Comparative evidence does not definitively favor cellular over acellular skin substitutes; when alternatives exist, document clinical justification for product selection in the medical record.

    • Include rationale (clinical factors or evidence citations) supporting the chosen product when similar alternatives are available.
    Documentation Required

    Use skin substitutes as adjuncts to standard care and document accordingly

    Skin substitutes are intended as adjuncts to standard wound care rather than first‑line monotherapy; documentation should reflect continued adjunctive use with standard treatments.

    • Record how the skin substitute was applied alongside standard care and the ongoing monitoring plan.
    Step Therapy

    Try and document 4–6 weeks of compression/standard care for VLUs before grafting

    For venous leg ulcers, follow guideline‑based expectations: attempt standard care with compression for 4–6 weeks and document serial wound measurements and response before applying skin substitutes; reapplication may be considered based on documented response.

    • Document serial measurements (area/perimeter/depth), number/position of ulcers, wound edge/base characteristics, drainage, and infection status when assessing response.
    Note

    Placeholder

    Placeholder — no summary provided in inventory.

    Note

    Placeholder

    Placeholder — no summary provided in inventory.

    Note

    No step therapy rules specified — standard medical necessity review applies

    No specific step‑therapy rules are specified in these sections; standard medical necessity review applies to other indications not described with explicit step therapy.

    • Apply usual policy clinical criteria and documentation requirements when step therapy is not specified.
    Note

    Placeholder

    Inventory item without detailed summary — no action specified.

    Note

    No step therapy requirements described here

    No step therapy requirements are described in these chunks; treat requests according to the policy's clinical criteria and documentation standards.

    • Refer to the main criteria for indications with explicit step therapy requirements.
    Note

    Step therapy not specified in this section

    Step therapy not specified in the revision excerpts — application limits and examples were updated but do not define step therapy rules.

    • Consult the main policy criteria for any required prior therapies.
    Note

    Revision history does not state step therapy requirements

    No step therapy requirements are stated in the revision‑history content; follow established policy criteria for prior care requirements.

    Note

    No step therapy requirements described in this section

    No step therapy requirements are described in this section; use the policy criteria and documentation checklist when evaluating requests.

    Note

    No step therapy requirements in revision history

    No step therapy requirements specified in the revision history excerpt — review the main policy for clinical prerequisites prior to approval.

    Note

    No step therapy requirements in this excerpt

    No step therapy requirements are described in this excerpt.

    Documentation Required

    Document ulcer number/position and measurements for repeat treatments

    For repeat treatments after the initial 12‑week period, document the number and position of ulcers and provide wound measurements (length, width, depth) for each ulcer.

    • Include clear documentation that the ulcer continues to improve based on serial measurements and wound descriptions.
    Documentation Required

    Ensure required clinical documentation is in the medical record

    Medical records must document wound/ulcer characteristics (including measurements), evidence of prior ineffective standard care with duration, and qualifying/disqualifying conditions (eg, HbA1c, ABI) to support medical necessity.

    • Include wound characteristics, precise measurements, prior treatment details and duration, and relevant labs/vital vascular assessments.
    Documentation Required

    Follow and document product IFU and labeled application instructions

    Follow and document product‑specific indications and application instructions (eg, apply to freshly debrided wounds per IFU) when selecting a product; reference the product IFU/labeling in the record as applicable.

    • Document wound bed preparation and that application followed the product's labeled instructions for use.
    Documentation Required

    Support coverage requests with peer‑reviewed evidence citations

    When requesting coverage, include references to the peer‑reviewed evidence that supports medical necessity for the specific product where available.

    • Attach citations or evidence summaries for product‑specific RCTs or systematic reviews when submitting PA or medical records.
    Documentation Required

    Provide clinical and billing documentation to support modifiers and associated services

    Clinical documentation must support use of modifiers (eg, JZ, 76) and include associated wound care services; for venous leg ulcers, document serial wound measurements and response to standard therapy when applicable.

    • Ensure modifier use is justified in the chart and that debridement/dressing care and follow‑up are documented.
    Documentation Required

    Ensure provider specialty and location align with wound care services

    Provider specialty and practice scope should align with wound care; geographic inconsistencies between patient and provider locations may be flagged for review.

    • Confirm provider credentials and practice setting are appropriate for performing and billing skin substitute applications.
    Documentation Required

    Document wound surface area to support application billing units

    Documentation must support the wound surface area reported for application billing units (eg, first 25 sq cm and each additional increment) to justify area‑based application codes.

    • Record precise wound surface area calculations used to determine the number of billing units.
    Billing Rule

    Document product‑specific coding and units to support claims

    Support claims by documenting product‑specific coding: when billing add‑on products, include documentation that justifies per‑cm2, per‑cc, or per‑mg billing and reference the corresponding Q‑code on the claim.

    • Match the billed Q‑code to the product listed in the policy and include unit justification in clinical notes.
    Note

    Anticipate claim‑level review for medical necessity and coding

    Expect claim‑level review for medical necessity, correct coding, and pricing; inclusion or omission of a code in the policy list does not guarantee reimbursement.

    • All unlisted codes are reviewed at claim level and may require prior authorization to avoid denial.
    Documentation Required

    Use policy references and IFU/FDA labeling to support documentation

    Extensive references and manufacturer IFU/FDA labeling links are provided in the policy references to support documentation of product indications and instructions for use; include these references in PA requests when relevant.

    • Use the policy reference list (eg, FDA labeling links, IFUs) to corroborate product‑specific application and indication statements in the record.
    Billing Rule

    Submit claims using current (post‑update) code sets

    Submit claims using current, post‑update code sets because the policy revision history documents multiple code set updates and annual reviews.

    • Verify that billed CPT/HCPCS/Q‑codes reflect the latest quarterly or annual code set updates referenced in the policy.
    Note

    Revision history notes code/application limit changes — follow main policy for PA/docs

    Revision history entries record code additions and application limit updates but do not specify provider documentation or PA procedures; follow the main policy criteria and payer PA process.

    • Use revision notes to identify changes but rely on the main coverage and authorization sections for procedural requirements.
    Note
    Note
    Note
    Denial Risk

    Claims may be denied if medical necessity criteria are not satisfied

    Claims will be denied when the policy's listed medical necessity criteria are not met; ensure all criteria (eg, ulcer size, infection status, prior therapy duration, vascular adequacy) are met and documented before billing.

    • Non‑covered indications and unmet criteria (see policy sections) are common causes for denials.
    Denial Risk

    Billing NMN‑listed products risks denial

    Use of many named products listed as Not Medically Necessary may trigger claim denial if billed for unsupported indications; verify product status in the NMN list before submission.

    • Cross‑check the product against the policy's NMN tables (chunks 18–27) prior to ordering or billing.
    Denial Risk

    Do not rely on FDA clearance alone to prevent denial

    FDA clearance alone does not establish coverage; claims submitted solely on the basis of FDA clearance/approval without meeting medical necessity criteria may be denied.

    • Document how the patient meets policy clinical criteria irrespective of regulatory status.
    Denial Risk

    Products without adequate evidence may be denied as not medically necessary

    Products lacking peer‑reviewed support, with poor‑quality literature, or without required FDA approval are considered not medically necessary and may be denied.

    • If evidence is limited or low quality for a product/indication, expect denial absent compelling documentation.
    Denial Risk

    Include associated wound care documentation to avoid denial/audit

    Claims for skin substitutes submitted without documentation of associated wound care services (eg, debridement, dressing changes, follow‑up) may be subject to denial or audit.

    • Include records of associated wound care services performed in the same episode of care to support the claim.
    Denial Risk

    Avoid billing manipulation — risk of audit/denial

    Billing manipulations (for example, splitting claims for the same date of service to bypass reimbursement thresholds) are prohibited and may trigger audit or denial.

    • Do not split or fragment claims to circumvent area/unit thresholds; document legitimately required units and intervals.
    Denial Risk

    Associated codes may be denied if primary product is NMN

    Codes billed in association with a primary product may also be denied if the primary product is determined to be Not Medically Necessary; ensure primary product meets criteria before billing associated codes.

    • Verify primary product coverage status to reduce risk of associated code denials.
    Billing Rule

    Do not bill add‑on codes without the required primary procedure

    Add‑on codes are frequently annotated as 'list separately in addition to primary procedure'; claims may be denied or misprocessed if add‑on codes are billed without the required primary procedure.

    • Ensure the primary procedure code is present on the claim when billing add‑on Q‑codes or A‑codes.
    Billing Rule

    Bill add‑on products as list‑separately with the correct Q‑code

    Add‑on products must be billed as 'list separately in addition to primary procedure' using the specified Q‑codes; failure to do so may result in claim denial.

    • Select the Q‑code corresponding to the product and unit of measure and include the primary procedure on the claim.
    Denial Risk

    Unlisted codes for non‑covered services will be denied; get PA for potentially covered unlisted codes

    If an unlisted code is submitted for non‑covered services addressed by this policy it will be denied as not covered; for potentially covered services using unlisted codes, prior authorization is recommended to avoid post‑service denial.

    • Obtain PA for unlisted codes when the service may be covered to prevent claim denial.
    Note

    Claims using outdated codes risk denial — verify recent code updates

    Policy revision history notes multiple quarterly code set updates; claims using out‑of‑date or incorrect codes may be subject to denial or require resubmission.

    • Verify the code effective dates and use the most current CPT/HCPCS/Q‑codes when submitting claims.
    Note

    Revision history excerpts do not list specific denial triggers

    Revision history does not provide explicit denial triggers in these excerpts; rely on the policy's stated medical necessity criteria and billing guidance for denial‑risk assessment.

    Denial Risk

    Claims may be denied if updated application limits (2/2026) are not met

    Updated application limits for venous stasis ulcers and diabetic foot ulcers were implemented in the 2/2026 annual review; claims not meeting the updated application limits may be denied.

    • Confirm product application limits and frequency prior to submitting claims, as policy limits were revised in 2/2026.
    Note

    Revision history section lacks denial‑risk details

    The revision‑history content does not specify denial risks in that section; use the main policy tables for denial criteria and NMN lists.

    Note
    Note
    Note
    Note

    Background, Definitions, and Evidence Summary

    Skin and tissue substitutes encompass a diverse group of products including allogenic acellular dermal matrices, biosynthetic dressings, cultured epidermal autografts, dermal regeneration/bilayer matrices, and human fibroblast‑derived temporary substitutes. These products are used as adjuncts to standard wound care or as components of reconstructive procedures depending on product labeling and the clinical indication.

    Partial-thickness burn (temporary covering indication) — definition and use-case
    DefinitionPartial-thickness (second-degree) burns involve epidermis and part of the dermis and may heal spontaneously; biosynthetic dressings may be used as temporary coverings on freshly debrided or excised partial-thickness burns
    Use-caseBiosynthetic dressings are indicated as temporary coverage for partial-thickness burns or to protect meshed autografts with low bacterial counts
    Application conditionApplied to freshly debrided/excised wounds or meshed autografts with <10^5 bacteria/g tissue per policy wording
    Skin substitutes — definition (bioengineered products classification)
    DefinitionSkin substitutes are bioengineered, tissue-engineered, or artificial skin products intended to protect wounds and reconstruct tissue; they may be cellular, acellular, or combination products
    ClassificationCellular, acellular, or combination — cellular substitutes may be autograft, allograft, or xenograft-based
    Clinical roleUsed as adjuncts to standard wound care when wound bed is prepared and infection is absent
    Burn depth classification — first/second/third-degree definitions
    First-degree burnInvolves epidermis only
    Second-degree (partial-thickness)Involves epidermis and part of the dermis
    Third-degree (full-thickness) and fourth-degreeThird-degree involves full epidermal and dermal layers requiring excision and grafting; fourth-degree involves deeper structures (tendon, muscle, bone)
    Wagner Ulcer Classification — DFU grading scale
    Wagner scale overviewWagner classification grades 0–5 based on ulcer depth and presence of infection or gangrene (0 no open lesion; 5 extensive gangrene)
    Clinical useUsed for diabetic foot ulcer depth staging to guide treatment decisions
    Severity examplesGrade 2: extension to ligament/tendon/joint without abscess; Grade 3: deep ulcer with abscess/osteomyelitis
    PMA-classified interactive wound dressing — definition and regulatory context
    DefinitionPMA-classified interactive wound dressings are FDA class III high-risk devices that actively promote healing by interacting with body tissues
    Regulatory contextThese products undergo the PMA approval process reflecting higher regulatory scrutiny for safety and effectiveness
    Clinical implicationPMA designation may influence coding and add-on/Q-code mapping in billing tables
    510(k) skin substitute — definition and regulatory context
    Definition510(k) skin substitutes are devices cleared via premarket notification, typically intended to protect wounds and support healing; they may or may not interact with tissues
    Coding note510(k) products are represented among Q-code groupings and may have 'not otherwise specified' Q-codes for billing
    Regulatory implication510(k) clearance is informational but does not alone establish coverage—medical necessity criteria still apply
    Humanitarian Device Exemption (HDE) — definition and oversight requirements
    DefinitionHumanitarian Device Exemption (HDE) permits marketing for conditions affecting fewer than 4,000 U.S. individuals/year and has IRB oversight requirements
    Evidence requirementHDE applications are not required to demonstrate effectiveness via valid clinical investigations
    Facility requirementsHDE devices may be used only in facilities with IRB approval and continuing review per FDA regulations
    Cultured epidermal autograft (Epicel) — HDE product definition and evidence note
    Epicel (cultured epidermal autograft)A cultured epidermal autograft product approved under an HDE for extensive burns; evidence includes nonrandomized studies for burn wounds
    Evidence noteEpicel's HDE approval means effectiveness evidence is limited; peer-reviewed nonrandomized studies have reported extensive permanent coverage in severe burns
    Use constraintHDE labeling limits use to indicated TBS thresholds (≥30% total body surface area per policy) and requires facility oversight
    Bilayer dermal regeneration (Integra) — bilayer matrix RCT evidence summary
    Integra descriptionBilayer dermal regeneration products (Integra family) are used for burns and some DFUs and have RCT evidence supporting increased complete wound closure
    Evidence summaryIntegra products are well-established in peer-reviewed literature as safe and effective for burn wounds
    Clinical roleUsed for post-excisional treatment when autograft unavailable or not desirable
    Dermal/skin substitute — definition referencing acellular human dermal allograft and bilayer cultured skin replacements
    DefinitionDermal/skin substitutes are biologic or bioengineered products (eg, acellular human dermal allograft, bilayer cultured skin replacements) used as adjuncts to standard care to promote wound healing
    Typical componentsIncludes acellular dermal matrices, bilayer matrices, cryopreserved placental membranes, cultured epidermal autografts, and biosynthetic dressings
    Adjunctive useRecommended as adjuncts when standard care has failed to progress (per NICE guidance)
    Standard care for venous leg ulcers — definition including compression therapy
    Standard care componentsStandard care for venous leg ulcers includes compression therapy and wound care measures
    When to consider substitutesSkin substitutes are suggested for difficult-to-heal ulcers that have failed to show healing after 4–6 weeks of standard care
    DocumentationSerial wound measurement and documentation is recommended to determine response before reapplication
    Area-based application codes — explanation of area-based reporting codes
    Area-based codes explainedArea-based application codes report application to a specified wound surface area (eg, first 25 sq cm, each additional 25 sq cm; first 100 sq cm, each additional 100 sq cm)
    PurposeUsed to justify billing of area-dependent application procedures and to align with product-specific Q-/C-codes
    ExamplesC5271–C5273 and G0681–G0684 are examples of area-based reporting codes
    Add-on code — definition of add-on billing designation
    DefinitionAn add-on code is billed separately in addition to a primary procedure code to report an adjunctive product or service
    Billing implicationAdd-on codes typically require a primary procedure and may be subject to denial if billed standalone
    Policy noteMany skin substitute Q-codes are designated add-on (list separately) per policy coding tables
    Add-on (list separately) — billing designation description
    Add-on (list separately) descriptionBilling designation indicating the product should be listed separately in addition to the primary procedure and reported using the specified Q-code
    Common requirementPolicy emphasizes use of the specified Q-code for add-on products to support claims
    Denial riskFailure to bill as list separately may result in claim denial or misprocessing
    Add-on, per square centimeter — billing descriptor used throughout lists
    Per cm2 add-on descriptorMany add-on product codes are billed per square centimeter (cm²) and annotated as 'add-on, list separately in addition to primary procedure'
    ConsistencyThis per-cm2 descriptor is used widely across Q-code listings in the policy
    Billing impactProviders must report applied area to match per-cm2 billing units for add-on codes
    Unlisted codes — definition and review process at claim level
    DefinitionUnlisted codes are procedure or product codes not explicitly listed in the policy and are reviewed for medical necessity and pricing at claim level
    Prior authorization recommendationFor potentially covered services using unlisted codes, prior authorization is recommended to avoid post-service denial
    Claim reviewUnlisted codes may require additional documentation and claim-level review for coverage determination
    skin and tissue substitutes — overarching definition
    Overarching definitionSkin and tissue substitutes include biologic and synthetic products used to treat burns, chronic wounds, and for reconstructive applications (eg, acellular dermal matrices, bilayer matrices, placental membranes, cultured grafts)
    Clinical roleUsed as adjuncts to standard wound care to protect wounds and promote tissue regeneration
    Coding relevanceVarious regulatory classifications (PMA/510(k)/361 HCT/P/HDE) map to different billing codes described in the policy
    application limits — policy-imposed limits on applications for specified conditions
    DefinitionApplication limits are policy-imposed limits on use (number/frequency/area) of skin and tissue substitute products for specified conditions
    Recent updateApplication limits for venous stasis ulcers and diabetic foot ulcers were updated in the 2/2026 annual review
    Coverage impactClaims not meeting updated application limits may be denied per policy revision notes
    criterion I — referenced coverage criterion to which examples were added during 2/2026 annual review
    Criterion I reference'Criterion I' is a referenced coverage criterion in the policy to which examples were added during the 2/2026 annual review
    Examples addedAnnual review entries indicate examples (numbered 1–4) were added to Criterion I to guide application
    Full text locationThe full Criterion I text and examples are referenced in the policy revision history but are contained in main criteria sections
    criterion I examples — examples added to criterion I referenced but not present in selected chunks
    StatusExamples were added to Criterion I during the 2/2026 annual review, but the explicit example text is not present in the provided excerpts
    Reference noteRevision-history entries repeatedly reference added examples (1–4) without including the example content in these chunks
    ActionRefer to full policy criteria tables for the actual examples added to Criterion I
    application limits — application limits updated for venous stasis and DFUs (definition entry)
    Updated application limits (2/2026)Application limits for venous stasis ulcers and diabetic foot ulcers were updated during the 2/2026 annual review
    Policy emphasisRevision-history entries emphasize that application limits and examples were modified to guide coverage and billing
    Provider impactProviders should ensure claims conform to the updated application limits to avoid denial
    venous stasis ulcers — referenced as clinical area with updated application limits
    Clinical area referencedVenous stasis ulcers are a primary clinical area with updated application limits noted in the 2/2026 review
    Coverage contextSkin substitutes for VLUs require failure of ≥4 weeks of standard venous care (eg, compression) and vascular adequacy per criteria
    Documentation requirementSerial wound measurements and evidence of response to standard care must be in the record
    diabetic foot ulcers — referenced as clinical area with updated application limits
    Clinical area referencedDiabetic foot ulcers are a primary clinical area with updated application limits noted in the 2/2026 review
    Coverage contextDFU coverage requires ulcer size 1–25 cm², A1c <12%, failure of ≥4 weeks standard care, vascular adequacy, and application limits (≤12 applications over 12 weeks for most products)
    Documentation requirementWound measurements, prior therapy duration, and qualifying lab/vascular data must be documented

    Policy Revision History and Updates

    2026-02annual_reviewLatest

    Annual review updated application limits for venous stasis ulcers and diabetic foot ulcers and added examples to criterion I.

    2026-01code_set_update

    Q1 2026 code set update: new CPT/HCPCS codes added.

    2025-10code_set_update

    Q4 2025 code set update: multiple codes added.

    2025-07code_set_update

    Q3 2025 code set update: codes added and termed codes noted.

    2025-04annual_review

    April 2025 annual review: additional codes added and termed codes noted.

    Operational note: the 2/2026 annual review updated application limits for venous stasis ulcers and diabetic foot ulcers and added examples to criterion I. Providers should be aware that these updates may affect prior authorization and claims processing and should use the current policy version and code sets when submitting requests or claims.

    The policy documents multiple periodic code set updates across 2024–2026. Providers and billing staff should track these updates, since changes to CPT/HCPCS code sets can affect claim handling and prior authorization requirements.

    Revision history shows general code set updates (including Q‑code additions) spanning Q4 2024 through Q1 2026. These administrative updates emphasize the need to reference the current code set when preparing claims and prior authorization requests.

    Quarterly code set updates were recorded for Q2–Q4 2025 and Q1–Q2 2026. Because codes and product mappings have changed across these updates, billing and authorization workflows should use the most recent code lists attached to the policy.

    The 2/2026 annual review specifically updated application limits for venous stasis ulcers and diabetic foot ulcers. These updated application limits may change allowable frequencies or total number of applications and should be verified against the current policy when requesting prior authorization or submitting claims.